Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all.
BACKGROUND
New cholesterol guidelines emphasize 10-year risk of cardiovascular disease (CVD) to identify adults eligible for statin therapy as primary prevention. Whether these CVD risk thresholds should be individualized by age and sex has not been explored.


OBJECTIVE
This study evaluated the potential impact of incorporating age- and sex-specific CVD risk thresholds into current cholesterol guidelines.


METHODS
Using data from the Framingham Offspring Study, this study assessed current treatment recommendations among age- and sex-specific groups in 3,685 participants free of CVD. Then, it evaluated how varying age- and sex-specific 10-year CVD risk thresholds for statin treatment affect the sensitivity and specificity for incident 10-year CVD events.


RESULTS
Basing statin therapy recommendations on a 10-year fixed risk threshold of 7.5% results in lower statin consideration among women than men (63% vs. 33%; p<0.0001), yet most of the study participants who were 66 to 75 years of age were recommended for statin treatment (90.3%). The fixed 7.5% threshold had relatively low sensitivity for capturing 10-year events in younger women and men (40 to 55 years of age). Sensitivity of the recommendations was substantially improved when the treatment threshold was reduced to 5% in participants who were 40 to 55 years of age. Among older adults (66 to 75 years of age), specificity was poor, but when the treatment threshold was raised to 10% in women and 15% in men, specificity significantly improved, with minimal loss in sensitivity.


CONCLUSIONS
Cholesterol treatment recommendations could be improved by using individualized age- and sex-specific CVD risk thresholds.
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. Electronic address: ann.navar@dm.duke.edu.
Ann Marie
AM
Navar-Boggan
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Eric D
ED
Peterson
Department of Mathematics and Statistics, Boston University, Boston, Massachusetts; Harvard Clinical Research Institute, Boston, Massachusetts.
Ralph B
RB
D'Agostino
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Michael J
MJ
Pencina
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, Canada.
Allan D
AD
Sniderman
D000328:Adult; D000367:Age Factors; D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D012737:Sex Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
cardiovascular disease; cholesterol treatment; sensitivity; specificity